Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPS1 | P31327 | 14/20 | 0.55 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1003506 | 0.87 | CPS1 (0.58) | CPS1HPGDKMT2AMEN1LMNA | |
| SCHEMBL30514003 | 0.84 | CPS1 (0.55) | CPS1HPGDKMT2AMEN1LMNA | |
| SCHEMBL17700424 | 0.81 | CPS1 (0.49) | CPS1HPGDKMT2AMEN1LMNA | |
| SCHEMBL18327552 | 0.80 | PDK2 (0.45) | CPS1KMT2ARAB9A | |
| SCHEMBL72082 | 0.80 | CPS1 (0.61) | CPS1HPGDKMT2AMEN1LMNA | |
| SCHEMBL17993989 | 0.78 | ESRRG (0.39) | HPGDKMT2AMEN1LMNAALDH1A1 | |
| SCHEMBL29639738 | 0.78 | ALDH1A1 (0.65) | CPS1HPGDKMT2AMEN1LMNA | |
| SCHEMBL531399 | 0.78 | ALDH1A1 (0.65) | CPS1HPGDKMT2AMEN1LMNA | |
| SCHEMBL1051747 | 0.78 | CPS1 (0.63) | CPS1HPGDKMT2AMEN1LMNA | |
| SCHEMBL25568108 | 0.77 | GAA (0.43) | LMNAALDH1A1GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362039-B2 | Therapeutic uses of compounds which selectively modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-29 | — | — | US | disclosed |
| EP-2342200-B1 | Compounds which selectively modulate the cb2 receptor | BOEHRINGER INGELHEIM INT (DE) | 2013-01-23 | — | — | EP | disclosed |
| US-8349871-B2 | Therapeutic uses of compounds which selectively modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-08 | — | — | US | disclosed |
| US-20120010184-A1 | Therapeutic Uses of Compounds Which Selectively Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-12 | — | — | US | disclosed |
| US-20110312932-A1 | Therapeutic Uses of Compounds Which Selectively Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
| US-8048899-B2 | Compounds which selectively modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-01 | — | — | US | disclosed |
| EP-2342200-A2 | COMPOUNDS WHICH SELECTIVELY MODULATE THE CB2 RECEPTOR | Boehringer Ingelheim International GmbH (DE) | 2011-07-13 | — | — | EP | disclosed |
| US-20100081644-A1 | Compounds Which Selectively Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-01 | — | — | US | disclosed |
| WO-2010036630-A2 | COMPOUNDS WHICH SELECTIVELY MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081644-A1 | Compounds Which Selectively Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | CPS1 4221/4885HPGD 711/4885KMT2A 3675/4885 |
| US-20110312932-A1 | Therapeutic Uses of Compounds Which Selectively Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | CPS1 3394/4885HPGD 589/4885KMT2A 3917/4885 |
| US-20120010184-A1 | Therapeutic Uses of Compounds Which Selectively Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | CPS1 3394/4885HPGD 589/4885KMT2A 3917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.